The pricing of new pharmaceutical products is crucial and must not be left to luck. If the price is set too high, the product may fail to gain reimbursement or be excluded from formularies. If the price is too low, profitability will be reduced. Thus, it is essential for pharmaceutical companies to fully understand the principles governing pricing and the market environment in which they are operating.

By Felicia Gentile, M.P.H. and Steven Bodovitz, Ph.D.
Published: September, 2004
220+ Pages - 24 Exhibits - 24 Companies Profiled

Over 75 tissue engineering products are under development for a wide array of applications such as nerve regeneration, hair growth and liver repair.

Tissue engineering is the generation of tissues to replace those that have been damaged or lost by disease. The ability to repair or replace tissue opens to door to the treatment of debilitating diseases and disorders such as Parkinson's disease, diabetes and traumatic injury - indications where current treatments are limited or nonexistent. Tissue engineered products, such as those to repair skin or cartilage, have been developed, but they have met with limited success. In order for the promise of tissue engineering to come to fruition, significant technical and market advances are required. Recent developments in stem cell technology, understanding the role of extracellular matrix in correct tissue growth, and improved production methods are some factors sparking new investment in this exciting field.

To purchase click - Tissue Engineering

By Rathin C. Das, PhD, MBA and K. John Morrow, Jr., PhD.
Published: September, 2004
600+ Pages - 100+ Exhibits - 30+ Company Profiles

Monoclonal Antibodies (MAb) have proven to be one of the most important medical breakthroughs of the past century. Indeed, in recent years, harnessing of the therapeutic power of the MAbs have produced treatments for various diseases with unmet medical needs, such as cancer, inflammation, allergy, autoimmune, and infectious diseases. Additionally, the design of innovative technologies has led to the discovery of a broader range of target antigens as well as wider applicability of MAbs. Currently, there are 18 therapeutic antibodies on the market and almost 200 more are in various stages of clinical development.

By Catherine M. Thomson, Ph.D. and William W. Ward, Ph.D.
Published: August, 2004
180+ Pages - 35+ Exhibits - 20 Company Profiles

Fluorescent proteins are fast providing novel insights into compound-induced responses in drug discovery. This is taking place from two key vantage points, namely, in real time and in living systems. With non-invasive, non-destructive properties along with the benefit of being genetically-encoded, fluorescent proteins are attractive candidates for tagging a promoter, gene, protein or drug target of interest, in drug discovery based on live-cell analysis.